Mather Group’s NovoCure NVCR Stock Holding History

Mather Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-15	Closed	-$234	–	2036
2024 Q2	$234	Buy	+15	New	+$264	﹤0.01%	2114

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mather Group's NVCR Position: Q3 2024 in Review

Mather Group sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 15 shares — an estimated $234 sold.

Mather Group first reported a position in NVCR in Q2 2024 and held it in 1 quarter. The position peaked at $234 in Q2 2024. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

Mather Group reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
Mather Group sold 15 NovoCure shares in Q3 2024, an estimated $234.
Mather Group first reported a position in NovoCure in Q2 2024 and held it in 1 quarter.
Mather Group's NovoCure position peaked at $234 in Q2 2024.
224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.